Roche's Tecentriq gets instant FDA review in tough-to-treat breast cancer

ZURICH: As the Swiss drugmaker seeks to be the first company to have its immunotherapy win approval in this indication, Roche's Tecentriq medicine will get a speedy review by US regulators in a tough-to-treat form of breast cancer.

Roche said that the US Food and Drug Administration (FDA) gave priority review to Tecentriq mixed with the chemotherapy Abraxane for initial treatment of people with metastatic triple-negative breast cancer whose tumours test positive for a protein, called PD-L1, that helps them avoid immune system detection.

The FDA's goal in priority reviews is to complete its work within six months, helping speed up the use of a medicine.